EBITDA

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

TMD Energy's new director, a capital markets expert, sparks a 6.6% stock gain and speculation of M&A or major fundraising on the horizon.

Glean's new AI assistant promises to move beyond search to autonomous action, tackling enterprise AI adoption challenges with deep contextual understanding.

Neurotech leader BrainsWay adjusts its share structure in a move to enhance liquidity, clarify valuation, and attract a broader base of global investors.

An Indiana firm's implantable pump gains key FDA status, promising a future with less mental burden for Type 1 Diabetes patients. But the road is long.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Cronos Group enters the premium vape race with its new 'liquid diamonds' PUFFERZ, facing immediate competition in Canada's booming all-in-one market.

Ceva's AI licensing revenue soared in 2025, securing deals with a top PC OEM and Microchip, signaling a major industry shift to on-device intelligence.

With 23,000 metres of drilling, Copper Giant aims to unlock one of the world's largest undeveloped copper caches, vital for the energy transition.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

A new report reveals why some indie restaurants thrive while others struggle, and it’s not just hard work. It's about access to strategic tools.

India's car-sharing leader posts a record quarter, slashing losses by 91% without marketing spend, and now eyes a US market uplisting and new capital.

Digital engineering firm Simform invests $3M to scale its Microsoft AI practice, aiming to capture market share with proprietary IP and a co-sell strategy.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

Warner Bros. Discovery pushes for a Netflix merger but opens a one-week window for Paramount Skydance to fix its flawed bid. A bidding war looms.

With all regulatory hurdles cleared, GDI makes a final push for shareholder approval on a $36.60 per share buyout from private equity firm Birch Hill.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.